Navigation Links
Halozyme to Host Second Quarter 2013 Financial Results Conference Call
Date:7/31/2013

SAN DIEGO, July 31, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the second quarter 2013 on Wednesday, August 7, 2013 at 4:30 p.m. ET/1:30 p.m. PT. Gregory I. Frost, President and Chief Executive Officer, will lead the call. On the same date post-market, Halozyme will release financial results for the second quarter 2013.

(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

The call will be webcast live through the "Investors" section of Halozyme's corporate website and a recording will be made available following the close of the call. To access the webcast, please log on to www.halozyme.com approximately fifteen minutes prior to the call to register, download, and install any necessary audio software. For those without access to the Internet, the live call may be accessed by phone by calling (877) 407-8037 (domestic callers) or (201) 689-8037 (international callers). A telephone replay will be available shortly after the call by dialing (877) 660-6853 (domestic callers) or (201) 612-7415 (international callers) using replay ID number 418819.

About Halozyme

Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, which increase the absorption and dispersion of biologics, drugs and fluids. Halozyme's pipeline addresses therapeutic areas, including diabetes, oncology and dermatology that have significant unmet medical need. The Company markets Hylenex® recombinant (hyaluronidase human injection) and has partnerships with Roche, Pfizer, Baxter, ViroPharma and Intrexon. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at www.halozyme.com.

Investor Contact:
David Ramsay
Halozyme Therapeutics
858-704-8260
ir@halozyme.com

Media Contact:
Nurha Hindi
Hill + Knowlton Strategies
818-522-8411
Nurha.Hindi@hkstrategies.com


'/>"/>
SOURCE Halozyme Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Halozyme to Host First Quarter 2012 Financial Results Conference Call
2. Halozyme Reports First Quarter 2012 Financial Results
3. Halozyme Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
4. Halozymes Ultrafast Insulin Formulations Improved Postprandial Glycemic Control in Patients Living with Type 1 Diabetes: Phase 2 Study Results Presented at ADA 2012
5. Halozyme Confirms Baxter Has Received A Complete Response Letter For HyQ BLA
6. Halozyme Reports Second Quarter 2012 Financial Results
7. Halozyme to Host Third Quarter Financial Results Conference Call
8. Halozyme Therapeutics To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
9. Halozyme Announced Roche Filed A Marketing Authorization Application For Subcutaneous MabThera
10. Halozyme Reports Fourth Quarter and Year End 2012 Financial Results
11. Halozyme Therapeutics to Present at the Barclays 2013 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... Ahead of today,s trading session, Stock-Callers.com draws investors, attention to ... close: Kite Pharma Inc. (NASDAQ: KITE ), BioPharmX Corp. ... Pharmaceuticals Inc. (NASDAQ: REGN ). According to a report ... 20 th , 2017, down on the day by about 0.5%. ... at: ...
(Date:1/23/2017)... -- A new Transparency Market Research report states that ... US$0.53 bn in 2013 and is predicted to touch US$2.38 bn ... and 2022. The title of the report is "Non-invasive Prenatal Testing ... and Forecast 2014 - 2022." ... Non-invasive prenatal testing (NIPT), also referred to as non-invasive ...
(Date:1/23/2017)... global  anxiety disorders and depression treatment market  is expected to reach a value ... anticipated to drive the market growth in the coming years. Increasing adoption of ... recent years. Continue Reading ... ... ...
Breaking Medicine Technology:
(Date:1/24/2017)... ... ... Have Dreamed: A Novel of Miracles”: a beautiful and poignant glimpse into the unexpected ... her life. “Who Would Have Dreamed: A Novel of Miracles” is the creation of published ... , Sharon shares that she started her spiritual journey later in life, but mentions, ...
(Date:1/24/2017)... ... 24, 2017 , ... Attention women who want bigger breasts ... autologous fat grafting—taking one’s own fat and putting it in other body part—is ... Cosmetic Surgeon and Medical Director of MilfordMD Cosmetic Dermatology Surgery & Laser Center, ...
(Date:1/24/2017)... (PRWEB) , ... January 23, 2017 , ... The January ... features a three-year outcome study on how outdoor behavioral healthcare (OBH) – also known ... distress and interpersonal difficulties while experiencing an increased sense of purpose both during and ...
(Date:1/24/2017)... , ... January 24, 2017 , ... The National Council ... for drug and alcohol awareness, have worked with communities to designate the last full ... January 23-29, 2017, the theme is “Shatter the Myths.” As a community, we ...
(Date:1/23/2017)... Jupiter Florida (PRWEB) , ... January 23, 2017 ... ... airing of the highly acclaimed series, Innovations with Ed Begley, Jr., scheduled to ... about the technology behind SmartCap, which was founded in 2008 to address the ...
Breaking Medicine News(10 mins):